Please login to the form below

Not currently logged in
Email:
Password:

GW Pharmaceuticals

This page shows the latest GW Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Orchard surpasses IPO expectations, raising $200m

Orchard surpasses IPO expectations, raising $200m

flow. Orchard now joins a cluster of European biotechs, including the likes of GW Pharmaceuticals and Genmab, that are worth 1bn or more.

Latest news

  • The year of the blockbuster The year of the blockbuster

    Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Epidiolex from GW Pharmaceuticals:With a PDUFA date

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent ... WEX Pharmaceuticals is conducting a

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    The drug, developed by GW Pharmaceuticals, was approved by Italian authorities in May and comes to the market with a reimbursed priced that GW said was “consistent with the reimbursed … price ... Sativex has been given a rolling launch in Europe,

  • GW Pharma says German Sativex pricing GW Pharma says German Sativex pricing "unacceptable"

    May pull MS drug from market. GW Pharmaceuticals and partner Almirall have said they may pull Sativex from the market in Germany after failing to agree a price for the drug ... GW said it would take an £800, 000 charge this fiscal year in connection

  • Novartis gains licence for GW's Sativex

    GW Pharmaceuticals has entered into an exclusive licence agreement for Novartis to commercialise Sativex in several key territories. ... GW Pharmaceuticals has entered into an exclusive licence agreement for Novartis to commercialise Sativex (cannabidiol;

More from news
Approximately 0 fully matching, plus 43 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Appoints Dr Volker Knappertz and Professor Ben Whalley. GW Pharmaceuticals has appointed Dr Volker Knappertz (pictured right) as its chief medical officer (CMO), a role that will see him based at ... I look forward to contributing to GW’s drug

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    And Scott Giacobello joins as chief financial officer. UK biopharma company GW Pharmaceuticals has promoted chief financial officer Adam George to UK managing director. ... Gover said: “These important leadership appointments reflect GW’s continuing

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    Appointed VP clinical research at company specialising in cannabinoids. Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma. ... Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics